Neurocrine price target raised to $195 from $188 at UBS

UBS analyst Ashwani Verma raised the firm’s price target on Neurocrine (NBIX) to $195 from $188 and keeps a Buy rating on the shares. Investor attention on Neurocrine centers on potential read-through from Medicare price negotiations for Teva’s (TEVA) Austedo, expected by late November, the analyst says in a research note. However, analysis of Ingrezza under IRA frameworks suggests these concerns may be overstated, with projections indicating stronger revenue potential beginning in 2029.